Novartis has received a blow in its Gilenya patent litigation – FiercePharma

Related Articles:

• GB Sciences Granted US Patent for Cannabinoid-based Formulations for Parkinson’s May 7, 2020 GB Sciences has been granted a patent from the U.S. Patent and Trademark Office (USPTO) covering the use of its proprietary cannabinoid-containing complex mixtures for treating Parkinson’s disease, the company announced. GB Sciences is creating a pipeline of new medicines based on cannabinoids, the pharmacologically active compounds that give the cannabis plant its medical and recreational properties. The patent — number 10,653,640…
• ADepTing to the UCB-Novartis deal December 6, 2021 # # # # Alpha synuclein has long been viewed at “Public enemy #1” by the Parkinson’s research community. This sticky, abundant protein starts to cluster (or aggregate) in Parkinson’s. There have been several attempts to reduce levels of the protein floating around outside of cells (using “immunotherapy” approaches) But now clinical research is ramping up to determine if reducing…
• Patients not patents February 13, 2022 # # # # Patent protection provides an inventor/discoverer with an exclusive right to prevent or stop others from commercially exploiting the patented invention for a set period of time. Patents are supposed to encourage innovation by providing the patent holder with an unchallenged opportunity to develop and profit from an idea. But it could be argued that patents are…
• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• Lobsor Pharmaceuticals Plans to Enter the U.S. Market with Treatment for Advanced Parkinson’s March 26, 2019 The United States Patent and Trademark Office (USPTO) has approved a patent covering the composition and method of administration of a new levodopa replacement formulation for treating Parkinson’s disease. Lecigon was developed by Lobsor Pharmaceuticals to be the next-generation of Stalevo (marketed by Novartis), a widely used oral therapy for earlier stages of Parkinson’s disease. It consists of a gel containing a…
• Intec Pharma Granted Hong Kong Patent for Carbidopa/Levodopa Pill for Parkinson’s July 25, 2017 Hong Kong has issued a patent to Intec Pharma for its investigational Accordion Pill Carbidopa/Levodopa (AP-CD/LD) drug delivery for Parkinson’s disease symptoms in advanced patients. The patent (HK1158545) is titled “Carbidopa/Levodopa Gastroretentive Drug Delivery” and is scheduled to remain active until April 2029. The patent belongs to Intec’s IN-7 patent family that already includes patents in the U.S., European Union, China, Japan, South Africa, and…
• MedRhythms’ Platform Using Music as Walking Aid Given US Patent April 27, 2020 MedRhythms, focused on creating treatments that incorporate music to aid people with walking problems due to neurological disorders, announced the issue of a new U.S. patent covering the audio engine of its digital therapeutics platform. The patent awarded by the United States Patent and Trademark Office is called “Enhancing Music for Repetitive Motion Activities.” MedRhythms’s technology centers around an intervention called Rhythmic…
• Annovis Given US Patent for Potential Parkinson’s Treatment Expected to Enter Phase 2 Trial February 24, 2020 Annovis Bio’s lead investigative therapy ANVS401 (also known as Posiphen) targeting protein buildup in the brain has been granted a U.S. patent as a way of treating Parkinson’s disease, Lewy body dementia, and other Lewy body disorders. The company, previously known as QR Pharma, expects that multiple patents for ANVS401 will be generated from this patent family, each independent and…
• Annovis Given US Patent for Potential Parkinson’s Treatment Expected to Enter Phase 2 Trial February 24, 2020 Annovis Bio’s lead investigative therapy ANVS401 (also known as Posiphen) targeting protein buildup in the brain has been granted a U.S. patent as a way of treating Parkinson’s disease, Lewy body dementia, and other Lewy body disorders. The company, previously known as QR Pharma, expects that multiple patents for ANVS401 will be generated from this patent family, each independent and…
• Blow by blow | WORLD - WORLD News Group June 3, 2021 Blow by blow | WORLD  WORLD News Group
• Watch now: Blow by blow, personal trainer helps Parkinson's sufferers fight disease - Madison.com December 25, 2021 Watch now: Blow by blow, personal trainer helps Parkinson's sufferers fight disease  Madison.com
• BMS, Pfizer and Merck face steep patent cliffs but all have the financial flexibility for M&A: Moody's - FiercePharma June 21, 2022 BMS, Pfizer and Merck face steep patent cliffs but all have the financial flexibility for M&A: Moody's  FiercePharma
• Year in review: 2021 December 31, 2021 # # # # As with the preceding year, 2021 proved to be challenging due to the continuing COVID-19 pandemic (and it is not over yet). Vaccines were rolled out with remarkable speed, but equally new variants of the virus popped up and have kept Governments and health regulatory bodies on their toes. An amazing feature of the last two…
• Gary Ellis is an Alabama Bright Light delivering a blow to Parkinson's disease - Alabama NewsCenter November 17, 2017 Alabama NewsCenterGary Ellis is an Alabama Bright Light delivering a blow to Parkinson's diseaseAlabama NewsCenterGary Ellis is an Alabama Bright Light delivering a blow to Parkinson's disease When Gary Ellis got a punch in the gut with a Parkinson's diagnosis, he decided to punch back by bringing Rock Steady Boxing to Gulf Shores. (Karim Shamsi-Basha / Alabama ...
• Paraquat Litigation Defendants Agree with Consolidation, Disagree with Location - Legal Examiner May 21, 2021 Paraquat Litigation Defendants Agree with Consolidation, Disagree with Location  Legal Examiner
• JPML Sends Herbicide Liability Litigation To Illinois - Law360 June 8, 2021 JPML Sends Herbicide Liability Litigation To Illinois  Law360
• Paraquat Litigation | Traverse City Injury Law News - Legal Examiner June 28, 2021 Paraquat Litigation | Traverse City Injury Law News  Legal Examiner
• Through litigation and studies, a connection between paraquat and Parkinson's disease is becoming known - The Apopka Voice July 13, 2021 Through litigation and studies, a connection between paraquat and Parkinson's disease is becoming known  The Apopka Voice
• Paraquat Parkinson's Disease Lawsuits Coordinated in Federal Multidistrict Litigation - Legal Examiner July 14, 2021 Paraquat Parkinson's Disease Lawsuits Coordinated in Federal Multidistrict Litigation  Legal Examiner
• Litigation alleging Syngenta's paraquat weed killer causes Parkinson's disease moving toward trial - US Right to Know - U.S. Right to Know October 29, 2021 Litigation alleging Syngenta's paraquat weed killer causes Parkinson's disease moving toward trial - US Right to Know  U.S. Right to Know
• Syngenta, Chevron Face Narrowed Paraquat Parkinson's Litigation - Bloomberg Law February 15, 2022 Syngenta, Chevron Face Narrowed Paraquat Parkinson's Litigation  Bloomberg Law
• Judge Chooses Six Cases to Move Toward Trial in Paraquat Litigation - West Virginia Injury Law News May 20, 2022 Judge Chooses Six Cases to Move Toward Trial in Paraquat Litigation  West Virginia Injury Law News